Phenergan and Phlebitis superficial - a phase IV clinical study of FDA data

Summary:

Phlebitis superficial is reported as a side effect among people who take Phenergan (promethazine hydrochloride), especially for people who are male, 40-49 old, also take Vicodin, and have Metastases to bone.

The phase IV clinical study analyzes which people have Phlebitis superficial when taking Phenergan. It is created by eHealthMe based on reports of 24,254 people who have side effects when taking Phenergan from the FDA, and is updated regularly.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

What is Phlebitis superficial?

Phlebitis superficial (inflammation of the walls of a vein-superficial) is found to be associated with 113 drugs and 213 conditions by eHealthMe. Check the latest studies of Phlebitis superficial.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

24,254 people reported to have side effects when taking Phenergan.
Among them, 12 people (0.05%) have Phlebitis superficial.

Could Phenergan cause Phlebitis superficial?

Among these 12 people:

What is the gender of people who have Phlebitis superficial when taking Phenergan? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Phlebitis superficial when taking Phenergan? *

What are other drugs people take besides Phenergan? *

What are other side effects people have besides Phlebitis superficial? *

Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 12 people, 100.00%
Pain: 12 people, 100.00%
Depression: 12 people, 100.00%
Weight Decreased: 12 people, 100.00%
Dehydration (dryness resulting from the removal of water): 12 people, 100.00%
Fatigue (feeling of tiredness): 12 people, 100.00%
Osteomyelitis (infection of bone): 10 people, 83.33%
Leukopenia (less number of white blood cells in blood): 10 people, 83.33%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 10 people, 83.33%
Oral Pain: 10 people, 83.33%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 10 people, 83.33%
Pain: 2 people, 16.67%
Migraine (headache): 2 people, 16.67%
Headache (pain in head): 2 people, 16.67%
Depression: 2 people, 16.67%
Stress Symptoms: 1 person, 8.33%
Stress And Anxiety: 1 person, 8.33%
Sleep Disorder: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Phenergan and have Phlebitis superficial?

- Check whether Phlebitis superficial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Phenergan:

Phenergan (25,312 reports)

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Phlebitis superficial:

Phlebitis superficial (113 drugs)

Browse all the conditions that are associated with Phlebitis superficial:

Phlebitis superficial (213 conditions)

Related publications that referenced our studies

Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .
Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on promethazine hydrochloride (the active ingredients of Phenergan) and Phenergan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.